secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2026-05-18T21:30:08+00:00
Accession:  0001193125-26-229173
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan reports initial Phase 1 data for CLN-978: B cell depletion and early efficacy in RA/SLE
--------------------------------------------------------------------------------

- As of Jan 14, 2026 cutoff, 14 patients dosed (5 RA, 9 SLE) across cohorts 1-3.
- B cell depletion >75% in 9/11 patients after 10 mcg; 3/6 below quantification after 20 mcg.
- 4/5 RA patients had DAS28-ESR decrease from high activity to moderate/remission.
- 5/6 SLE patients had SLEDAI score decrease >4 points; ultrasound synovitis improved in 3/4 RA.
- CLN-978 well tolerated; dose escalation continues; updated data at EULAR June 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526229173/0001193125-26-229173-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312526229173/cgem-20260518.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-229173

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer